Drug Trial Radar · NCT06711887
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
May 19, 2025
Primary completion
Aug 1, 2035
Study completion Aug 1, 2035
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treatment at the end of the SIRIUS-LN core study, and 2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
Conditions
- Lupus Nephritis
Interventions
IanalumabDrug
Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Time to renal flare, increase in immunosuppressive medication, or deathTime frame: Between Week 144E1 and EOS (up to Week 456)
- Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
Locations
53 sites in 18 countries. Site status is shown where the registry gives one.
Circuit Clinical
Orchard Park, New York · Recruiting
Novartis Investigative Site
Vitória, Espírito Santo, Brazil · Recruiting
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil · Recruiting
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Novartis Investigative Site
Recife, Pernambuco, Brazil · Recruiting
Novartis Investigative Site
Santo André, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Beijing, China · Active not recruiting
Novartis Investigative Site
Chongqing, China · Recruiting
Novartis Investigative Site
Guangzhou, China · Recruiting
Novartis Investigative Site
Guangzhou, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Recruiting
Novartis Investigative Site
Shantou, Guangdong, China · Active not recruiting
Novartis Investigative Site
Shenzhen, Guangdong, China · Recruiting
Novartis Investigative Site
Liuzhou, Guangxi, China · Recruiting
Novartis Investigative Site
Wuhan, Hubei, China · Recruiting
Novartis Investigative Site
Changchun, Jilin, China · Recruiting
Novartis Investigative Site
Shenyang, Liaoning, China · Recruiting
Novartis Investigative Site
Binzhou, Shandong, China · Recruiting
Novartis Investigative Site
Ningbo, Zhejiang, China · Recruiting
Novartis Investigative Site
Medellín, Antioquia, Colombia · Recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Olomouc, Czechia · Active not recruiting
Novartis Investigative Site
Prague, Czechia · Recruiting
Novartis Investigative Site
Grenoble, France · Recruiting
Novartis Investigative Site
Guatemala City, Guatemala · Recruiting
Novartis Investigative Site
Guatemala City, Departamento de Guatemala, Guatemala · Recruiting
Novartis Investigative Site
Quetzaltenango, Departamento de Quetzaltenango, Guatemala · Recruiting
Novartis Investigative Site
Tuenmen, Hong Kong · Recruiting
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting
Novartis Investigative Site
Sibu, Sarawak, Malaysia · Recruiting
Novartis Investigative Site
Oaxaca City, Mexico · Recruiting
Novartis Investigative Site
Querétaro, Mexico · Recruiting
Novartis Investigative Site
León, Guanajuato, Mexico · Recruiting
Novartis Investigative Site
Monterrey, Nuevo León, Mexico · Recruiting
Novartis Investigative Site
Bucharest, Romania · Recruiting
Novartis Investigative Site
Oradea, Jud Bihor, Romania · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.